Healthcare shares are lower in pre-market trade. RadNet (
) reported Q2 2013 net income of $2.7 million, or $0.07 per diluted
share, compared to a net income of $2.9 million, or $0.07 per
diluted share, in the same period last year.
Net service fee revenue totaled $176.5 million versus $165.4
million in the prior-year period. No analyst estimates were
available for comparison. For 2013, RadNet reaffirmed its revenue
guidance of $700 million - $730 million. RDNT is flat at $3.16 in
And, Horizon Pharma (
) reports net sales for Q2 2013 were $17.6 million and $12.3
million, respectively, increases of 64% and 34%, respectively,
versus Q1 2013. HZNP is flat at $2.42 pre-bell.
Non-GAAP net loss for Q2 2013, was $15.0 million, or $0.24 per
share, compared to a non-GAAP net loss of $20.6 million, or $0.62
per share, for Q2 2012. Analysts expected a loss of $0.32 per share
on 16.09 million in revenue.
Finally, Progenix Pharmaceuticals (
) reported a Q2 net loss of $12.3 million, or $0.24 diluted per
share, compared to net loss of $10.7 million, or $0.32 last year,
and bang in line with expectations.
Q2 revenue totaled $1.8 million, unchanged from the 2012 period
and just shy of forecasts for $1.86 million. The shares closed down
8% on Thursday at $5.27, but remain in the upper band of the
52-week range of $1.41 - $6.47.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.